News

A study found when ribociclib, a targeted therapy drug, is added to hormone therapy there are a significant invasive disease-free survival benefit in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.

Results of a trial of pirtobrutinib highlight the drug’s impact and potential for pre-treated mantle cell lymphomas.

New spatial tools measure how fast nutrients in tumors flow through different pathways, identifying pathways whose activities are uniquely elevated in brain cancer and offering clues for potential treatment strategies.

Prostate-specific antigen (PSA) levels are the main biomarker for prostate cancer, and new research has shown how accounting for genetic differences can make PSA screening for cancer more accurate.

Fighting relapsed/refractory lymphoma during pregnancy requires critical decision-making from patients and providers, yet prior to this study, no data existed to inform these choices.

In crisis, the nucleus calls antioxidant enzymes to the rescue. The nucleus being metabolically active is a profound paradigm shift with implications for cancer research.

A new research collaboration paves the way for new models to accelerate discoveries.

Understanding the link between the gut microbiome and polyp growth opens the door to potential screenings and treatments.

Scientists have discovered a novel approach that improves the efficacy of immune checkpoint inhibitor cancer treatment and minimizes the associated side effects.

A two-pronged stem cell therapy has been developed in a new study, which shows can suppress tumor growth and prolong survival in preclinical animal models.